Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium Joins Top 10 Rx Brands; Amgen Is First Biotech On Top 10 Pharma List, IMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Nexium is the seventh largest pharmaceutical in the U.S. and may be on track to reclaim Prilosec's number four position this year. Pfizer has four of the top 10 brands and more than a $10 bil. sales lead over GSK.

You may also be interested in...



Dueling Messages For Pharma From US Medicaid Formulary Plan

The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.

A Tale Of Two DMD Drugs: Theme And Variation In Controversial US FDA Reviews

Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.

US FDA ‘Public Health’ Approach To Opioids May Open Up Pricing Debates

Latest effort by FDA to re-set reviews for novel opioid analgesics is off to a rocky start after three advisory committee reviews. One unintended consequences may already be apparent: by taking a broad, public health perspective on new formulations, the agency may be inviting arguments based on price.

Topics

UsernamePublicRestriction

Register

PS058619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel